Financial Performance - The company's total revenue for the first half of 2025 was 228 million yuan, a decrease of 9.28 million yuan compared to the same period last year, representing a year-on-year decline of 3.91% [1] - The net profit attributable to shareholders was 42.68 million yuan, with net cash inflow from operating activities amounting to 25.57 million yuan [1] Financial Ratios - The latest debt-to-asset ratio is 13.85%, which is an increase of 1.62 percentage points from the previous quarter and an increase of 4.65 percentage points compared to the same period last year [3] - The latest gross profit margin stands at 54.70%, with a return on equity (ROE) of 3.09% [3] Efficiency Metrics - The diluted earnings per share (EPS) is 0.39 yuan [4] - The total asset turnover ratio is 0.14 times, a decrease of 0.02 times compared to the same period last year, reflecting a year-on-year decline of 10.53% [4] - The inventory turnover ratio is 0.75 times, down by 0.60 times from the same period last year, indicating a year-on-year decline of 44.45% [4] Shareholder Information - The number of shareholders is 12,500, with the top ten shareholders holding 73.30 million shares, accounting for 67.69% of the total share capital [4]
科源制药(301281.SZ)：2025年中报净利润为4268.30万元